Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences (GILD) continues to show strong performance in the biotechnology sector, with its HIV treatment Biktarvy generating $13.4 billion in sales for 2024, marking a 13% increase from the previous year. This substantial revenue accounted for nearly 46% of Gilead's total sales of $28.8 billion. The company's growth illustrates...

Gilead Sciences Reports Strong Revenue Growth and Prepares for Competitive Launch in HIV Prevention Market Amid Broader Market Challenges